Table 2. Association of patient/tumor characteristics to pCR in univariate analysis.
| Variables | N (%) (n=67) | pCR, n (%) (n=20) | OR | 95% CI | P value |
|---|---|---|---|---|---|
| Age (years) | |||||
| ≤50 | 25 (37.3) | 4 (16.0) | 1.000 | ||
| >50 | 42 (62.7) | 16 (38.1) | 0.481 | 0.099–1.187 | 0.083 |
| Histologic type | |||||
| Lobular | 1 (1.5) | 0 (0.0) | No | ||
| Others | 3 (4.5) | 1 (33.3) | 1.000 | No | No |
| Ductal | 63 (94.0) | 19 (30.2) | 1.020 | 0.140–14.609 | 1.000 |
| Grade | |||||
| Unknown | 4 (6.0) | 2 (50) | 1.000 | ||
| G1 | 6 (9.0) | 2 (33.3) | 2.000 | 0.150–26.734 | 0.600 |
| G2 | 42 (62.7) | 11 (26.2) | 3.200 | 0.398–25.733 | 0.274 |
| G3 | 15 (22.4) | 5 (33.3) | 2.000 | 0.214–18.687 | 0.543 |
| Ki-67 | |||||
| <14% | 7 (10.4) | 1 (14.3) | 1.000 | ||
| ≥14% | 60 (89.6) | 19 (31.7) | 0.392 | 0.040–3.200 | 0.665 |
| Hormone receptor | |||||
| Negative | 33 (49.3) | 14 (42.4) | 1.000 | ||
| Positive | 34 (50.7) | 6 (17.6) | 1.789 | 1.179–11.178 | 0.021* |
| HER2 | |||||
| Negative | 33 (49.3) | 5 (15.2) | 1.000 | ||
| Positive | 34 (50.7) | 15 (44.1) | 0.426 | 0.073–0.756 | 0.012* |
| Molecular subtype | |||||
| Triple negative | 12 (17.9) | 4 (33.3) | 1.000 | ||
| Luminal A | 8 (11.9) | 0 (0.0) | No | No | No |
| Luminal B/HER2− | 13 (19.4) | 0 (0.0) | No | No | No |
| Luminal B/HER2+ | 13 (19.4) | 5 (38.5) | 0.800 | 0.155–4.123 | 0.790 |
| HER2 enriched | 21 (31.3) | 11 (52.4) | 0.550 | 0.126–2.403 | 0.427 |
| Chemotherapy regimen | |||||
| Chemo + trastuzumab | 28 (41.8) | 12 (42.9) | 1.000 | ||
| Various | 12 (17.9) | 1 (8.3) | 0.140 | 0.038–3.518 | 0.382 |
| Anthracycline and taxane | 25 (37.3) | 5 (20.0) | 1.364 | 1.016–2.247 | 0.038* |
| Unknowna | 2 (3.0) | 2 (100) | |||
| NLR | |||||
| High | 22 (32.8) | 10 (45.5) | 1.000 | ||
| Low | 45 (67.2) | 10 (22.2) | 0.676 | 0.118–1.056 | 0.580 |
| PLR | |||||
| High | 48 (71.6) | 19 (37.5) | 1.000 | ||
| Low | 19 (28.4) | 1 (10.5) | 1.540 | 1.203–1.970 | 0.007* |
| NLR/PLR | |||||
| High/high | 19 (28.4) | 9 (47.4) | 1.000 | ||
| Low/high | 30 (44.8) | 9 (30.0) | 2.100 | 0.638–6.916 | 0.222 |
| High/low | 4 (6.0) | 0 (0.0) | No | No | No |
| Low/low | 14 (20.9) | 2 (14.3) | 11.700 | 1.265–108.200 | 0.030* |
| Surgery | |||||
| Mastectomy | 61 (91.0) | 18 (29.5) | 1.000 | ||
| Breast-conserving surgery | 6 (9.0) | 2 (33.3) | 1.175 | 0.201–7.114 | 1.000 |
*, significant values; a, unknown, not included in the analysis. CI, confidence interval; HER2, human epidermal growth factor receptor 2; NLR, neutrophil-to-lymphocyte ratio; OR, odds ratio; pCR, pathologic complete response; PLR, platelet-to-lymphocyte ratio.